Baicalein inhibits proliferation and migration of bladder cancer cell line T24 by down-regulation of microRNA-106.
The high incidence and relapse make bladder cancer become a public health problem. Although the anti-tumor role of baicalein (BAI) in bladder cancer has been reported, the details of regulatory mechanism and the interaction between BAI and microRNAs (miRs) remain unclear. We aimed to explore the regulatory mechanisms of BAI in bladder cancer. T24 cell viability after BAI treatments was measured by Cell Counting Kit-8 assay. Then, effects of BAI on proliferation, apoptosis, migration and expressions of proteins involved were assessed by BrdU incorporation assay, flow cytometry assay, Transwell cell migration assay and Western blot analysis, respectively. We subsequently testified the miR-106 and p21 level using stem-loop RT-PCR. In addition, whether BAI affected T24 cells through regulating miR-106 was verified. Double luciferase reporter assay was used to determine a target of miR-106. The involvements of the c-Jun N-terminal protein kinase (JNK) and mitogen-activated protein kinase kinase (MEK)/ extracellular signal-regulated kinase (ERK) pathways were finally measured. First of all, we verified that BAI could repress proliferation and migration, and promote apoptosis. Then, we interestingly identified that miR-106 level was decreased by BAI stimulation. After that, miR-106 overexpression was found to significantly reverse the effects of BAI on proliferation, migration and apoptosis of T24 cells. p21 was a target of miR-106. Finally, phosphorylated levels of JNK, MEK and ERK were reduced by BAI, and those reductions were reversed by miR-106 overexpression. Furthermore, phosphorylated levels of JNK, MEK and ERK were reduced by p21 upregulation. BAI suppressed proliferation and migration, and induced apoptosis of T24 cells through down-regulating miR-106, along with inhibition of the JNK and MEK/ERK pathways.